Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes (Liratime)

This study has been completed.
Novo Nordisk A/S
Information provided by (Responsible Party):
Peter Rossing, Steno Diabetes Center Identifier:
First received: December 12, 2011
Last updated: January 30, 2015
Last verified: July 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2014
  Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):